Carmustine

Generic Name
Carmustine
Brand Names
Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
Drug Type
Small Molecule
Chemical Formula
C5H9Cl2N3O2
CAS Number
154-93-8
Unique Ingredient Identifier
U68WG3173Y
Background

A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...

Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Associated Conditions
Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-
Clinical Trials
Related News

Auto Stem Cell Transplant for Lymphoma Patients

First Posted Date
2017-04-24
Last Posted Date
2024-11-04
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
150
Registration Number
NCT03125642
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

First Posted Date
2017-03-07
Last Posted Date
2023-11-28
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
14
Registration Number
NCT03072771
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

First Posted Date
2017-01-12
Last Posted Date
2023-02-16
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
22
Registration Number
NCT03019640
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

First Posted Date
2016-09-12
Last Posted Date
2024-03-15
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
86
Registration Number
NCT02896582
Locations
🇫🇷

CHU d'Angers, Angers, France

🇫🇷

CHU d'Amiens, Amiens, France

🇫🇷

CH d'Avignon, Avignon, France

and more 27 locations

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

First Posted Date
2016-06-13
Last Posted Date
2024-07-31
Lead Sponsor
AIDS Malignancy Consortium
Target Recruit Count
11
Registration Number
NCT02797470
Locations
🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients

First Posted Date
2016-02-01
Last Posted Date
2020-01-14
Lead Sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Target Recruit Count
20
Registration Number
NCT02670109
Locations
🇲🇽

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

First Posted Date
2015-07-21
Last Posted Date
2020-11-23
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
11
Registration Number
NCT02504359
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

First Posted Date
2015-06-26
Last Posted Date
2020-11-23
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
3
Registration Number
NCT02483000
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

First Posted Date
2015-05-13
Last Posted Date
2024-11-14
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
302
Registration Number
NCT02443077
Locations
🇺🇸

Logan Health Medical Center, Kalispell, Montana, United States

🇺🇸

Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States

🇺🇸

Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States

and more 279 locations

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL

First Posted Date
2015-02-19
Last Posted Date
2018-03-12
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
3
Registration Number
NCT02366663
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy